WO2007148235A3 - Acides nucléiques apparentés au cancer - Google Patents

Acides nucléiques apparentés au cancer Download PDF

Info

Publication number
WO2007148235A3
WO2007148235A3 PCT/IB2007/003116 IB2007003116W WO2007148235A3 WO 2007148235 A3 WO2007148235 A3 WO 2007148235A3 IB 2007003116 W IB2007003116 W IB 2007003116W WO 2007148235 A3 WO2007148235 A3 WO 2007148235A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
cancer
related nucleic
polynucleotides
cancers
Prior art date
Application number
PCT/IB2007/003116
Other languages
English (en)
Other versions
WO2007148235A2 (fr
Inventor
Ranit Aharonov
Nitzan Rosenfeld
Hila Benjamin
Original Assignee
Rosetta Genomics Ltd
Ranit Aharonov
Nitzan Rosenfeld
Hila Benjamin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/418,875 external-priority patent/US7592441B2/en
Priority claimed from US11/418,718 external-priority patent/US20070259349A1/en
Priority claimed from US11/418,870 external-priority patent/US7825229B2/en
Priority claimed from US11/429,720 external-priority patent/US7642348B2/en
Application filed by Rosetta Genomics Ltd, Ranit Aharonov, Nitzan Rosenfeld, Hila Benjamin filed Critical Rosetta Genomics Ltd
Priority to US12/298,065 priority Critical patent/US20090186353A1/en
Publication of WO2007148235A2 publication Critical patent/WO2007148235A2/fr
Priority to IL195066A priority patent/IL195066A0/en
Publication of WO2007148235A3 publication Critical patent/WO2007148235A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

L'invention concerne des polynucléotides associés à des types de cancers spécifiques. Lesdites polynucléotides sont des ARNmi, des précurseurs de l'ARNmi, ainsi que des acides associés. L'invention concerne également des méthodes et des compositions pouvant s'utiliser pour établir des diagnostics, des pronostics, ainsi que le traitement de différents cancers.
PCT/IB2007/003116 2004-10-04 2007-05-04 Acides nucléiques apparentés au cancer WO2007148235A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/298,065 US20090186353A1 (en) 2004-10-04 2007-05-04 Cancer-related nucleic acids
IL195066A IL195066A0 (en) 2006-05-04 2008-11-03 Cancer-related nucleic acids

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US11/418,875 US7592441B2 (en) 2004-10-04 2006-05-04 Liver cancer-related nucleic acids
US11/418,718 2006-05-04
US11/418,875 2006-05-04
US11/418,718 US20070259349A1 (en) 2006-05-04 2006-05-04 Bladder cancer-related nucleic acids
US11/418,870 US7825229B2 (en) 2005-03-25 2006-05-04 Lung cancer-related nucleic acids
US11/418,870 2006-05-04
US11/429,720 US7642348B2 (en) 2004-10-04 2006-05-08 Prostate cancer-related nucleic acids
US11/429,720 2006-05-08
US82524706P 2006-09-11 2006-09-11
US60/825,247 2006-09-11

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US11/418,875 Continuation-In-Part US7592441B2 (en) 2004-10-04 2006-05-04 Liver cancer-related nucleic acids
US11/429,720 Continuation-In-Part US7642348B2 (en) 2004-10-04 2006-05-08 Prostate cancer-related nucleic acids

Publications (2)

Publication Number Publication Date
WO2007148235A2 WO2007148235A2 (fr) 2007-12-27
WO2007148235A3 true WO2007148235A3 (fr) 2009-04-30

Family

ID=38833834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003116 WO2007148235A2 (fr) 2004-10-04 2007-05-04 Acides nucléiques apparentés au cancer

Country Status (2)

Country Link
IL (1) IL195066A0 (fr)
WO (1) WO2007148235A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563252B2 (en) 2004-05-14 2013-10-22 Rosetta Genomics Ltd. Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
CA2677043A1 (fr) * 2007-03-01 2008-09-04 Rosetta Genomics Ltd. Procedes pour distinguer un carcinome squameux du poumon d'autres cancers du poumon a non-petites cellules
WO2009119809A1 (fr) * 2008-03-27 2009-10-01 株式会社ミラキュア Marqueur pour la détermination du cancer du sein, méthode d'essai, et kit d'essai
JP5750710B2 (ja) * 2008-04-30 2015-07-22 日本電気株式会社 癌マーカー、それを用いた癌の評価方法および評価試薬
US9068232B2 (en) * 2008-08-06 2015-06-30 Rosetta Genomics Ltd. Gene expression signature for classification of kidney tumors
US20110160086A1 (en) * 2008-08-06 2011-06-30 Rosetta Genomics Ltd. Gene expression signature for classification of kidney tumors
WO2010018563A2 (fr) * 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions et procédés de pronostic d'un lymphome
US8557786B2 (en) 2008-08-19 2013-10-15 Maine Institute of Human Genetics and Health Micro RNA (MiRNA) and neurofibromatosis type 1: a role in diagnosis and therapy
EP2358902A1 (fr) * 2008-12-10 2011-08-24 Universität Regensburg Compositions et procédés pour le profilage de l'expression de micro-arn de cellules souches cancéreuses
US9150919B2 (en) * 2009-04-16 2015-10-06 Padma Arunachalam Methods and compositions to detect and differentiate small RNAs in RNA maturation pathway
WO2011014697A1 (fr) * 2009-07-31 2011-02-03 The Translational Genomics Research Institute Méthodes d’évaluation du risque de progression d’un cancer
WO2011024157A1 (fr) * 2009-08-23 2011-03-03 Rosetta Genomics Ltd. Séquences d'acides nucléiques liées au cancer
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011154008A1 (fr) 2010-06-11 2011-12-15 Rigshospitalet Classification de micro-arn de néoplasie folliculaire de la thyroïde
JP5755849B2 (ja) * 2010-07-06 2015-07-29 東レ株式会社 胃がんの補助化学療法感受性判定用組成物又はキット
EP2772550B1 (fr) 2010-11-17 2017-03-29 Interpace Diagnostics, LLC Micro-ARN comme biomarqueurs pour différencier des néoplasmes de thyroïde bénins et malins
WO2012161124A1 (fr) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 Composition contenant un micro arn ou système d'expression associé
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
JP7116463B2 (ja) * 2015-10-30 2022-08-10 典正 三浦 Ｄｎａ損傷を修復するｒｎａ分子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants

Also Published As

Publication number Publication date
IL195066A0 (en) 2011-08-01
WO2007148235A2 (fr) 2007-12-27

Similar Documents

Publication Publication Date Title
WO2007148235A3 (fr) Acides nucléiques apparentés au cancer
WO2009108866A3 (fr) Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
WO2005111211A8 (fr) Micro-arn et utilisations de ceux-ci
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
WO2005116250A3 (fr) Arnmi viraux ou associes aux virus et leur utilisation
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2007134210A8 (fr) Méthodes et compositions destinées au diagnostic et au traitement du cancer
WO2009108856A3 (fr) Signatures de microarn associées à la leucémie lymphoïde chronique humaine (llc) et leurs utilisations
EP2327798A8 (fr) MicroARN et leurs utilisations
EP2257647A4 (fr) Procédés et compositions fondés sur micro arn pour le diagnostic, le pronostic et le traitement du cancer de l'estomac
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
WO2008073915A3 (fr) Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
WO2008078180A3 (fr) Matériaux et procédés pour la génération de transcrits comprenant des nucléotides modifiés
EP1978986A4 (fr) Procédés et compositions basés sur des micro-arn et s'appliquant au diagnostic, au pronostic et au traitement du cancer du poumon
WO2009108860A8 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
CA2840149C (fr) Methodes et acides nucleiques permettant d'etablir le pronostic d'un sujet atteint de cancer
WO2012068400A3 (fr) Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
WO2009055773A3 (fr) Méthodes pour identifier une interaction du gène 'fragile histidine triad' (fhit) et utilisations associées
WO2010135692A3 (fr) Biomarqueurs miarn d'une maladie prostatique
WO2008087040A3 (fr) Procédés et acides nucléiques pour analyses des troubles prolifératifs cellulaires
WO2010065630A3 (fr) Compositions et procédés de traitement d'une néoplasie hépatique
WO2009074328A3 (fr) Methodes et acides nucleiques permettant d'analyser les troubles de la proliferation cellulaire
WO2008092099A8 (fr) Compositions et procédés de traitement de malignités hématopoïétiques
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2010058393A3 (fr) Compositions et procédés pour le pronostic du cancer du côlon

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12298065

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07845192

Country of ref document: EP

Kind code of ref document: A2